

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-----------------------------|-------------------|
| Application Number | 10/583,927 |
| Filing Date | December 23, 2004 |
| First Named Inventor | Sek Chung Fung |
| Art Unit | 1643 |
| Examiner Name | To Be Assigned |
| Attorney Docket No. | 12279-187-999 |

U.S. PATENT DOCUMENTS

| *Examiner Initials | Cite No. | Document Number – Kind Code | Publication Date mm/dd/yyyy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|----------|-----------------------------|-----------------------------|---|---|
| | A01 | 12/240,604 | 12/29/2008 | Fung et al. | |
| | A02 | 5,011,778 | 04/30/1991 | Newman et al. | |
| | A03 | 5,359,037 | 10/25/1994 | Wallach et al. | |
| | A04 | 5,596,072 | 1/21/1997 | Culpepper et al. | |
| | A05 | 5,677,165 | 10/14/1997 | De Boer et al. | |
| | A06 | 5,705,154 | 01/06/1998 | Dalie et al. | |
| | A07 | 5,710,023 | 01/20/1998 | Collins et al. | |
| | A08 | 5,717,072 | 02/10/1998 | Mosley et al. | |
| | A09 | 5,747,037 | 05/05/1998 | Noelle et al. | |
| | A10 | 5,783,181 | 07/21/1998 | Browne et al. | |
| | A11 | 6,156,321 B1 | 12/05/2000 | Thorpe et al. | |
| | A12 | 6,468,528 B1 | 10/22/2002 | Mak et al. | |
| | A13 | 6,911,530 B1 | 06/28/2005 | Willson et al. | |
| | A14 | 7,078,494 | 07/18/2006 | Collins et al. | |
| | A15 | 7,078,496 B1 | 07/18/2006 | Collins et al. | |
| | A16 | 7,312,024 B2 | 12/25/2007 | Mak et al. | |
| | A17 | 7,553,487 B2 | 06/30/2009 | Collins et al. | |
| | A18 | 2003/0049257 A1 | 03/13/2003 | Mak et al. | |
| | A19 | 2005/0277126 A1 | 12/15/2005 | Collins et al. | |
| | A20 | 2008/0008648 A1 | 01/10/2008 | Fung et al. | |

FOREIGN PATENT DOCUMENTS

| *Examiner Initials | Cite No. | Foreign Patent Document Country Code, Number, Kind Code (if known) | Publication Date mm/dd/yyyy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|--------------------|----------|--|-----------------------------|---|---|---|
| | B01 | EP 1 270 595 A1 | 1/02/2003 | Kyowa Hakko Kogyo Co., Ltd. | | |
| | B02 | EP 1 327 681 A1 | 7/16/2003 | Chugai Seiyaku Kabushiki Kaisha | | |
| | B03 | EP 1 646 656 A2 | 1/27/2005 | Cambridge Antibody Technology Limited | | X |
| | B04 | WO 00/15663 | 3/23/2000 | Cancer Research Campaign Technology Limited | | |

NYI-4201601v2

**EXAMINER
SIGNATURE****DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-----------------------------|-------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | Application Number | 10/583,927 |
| | Filing Date | December 23, 2004 |
| | First Named Inventor | Sek Chung Fung |
| | Art Unit | 1643 |
| | Examiner Name | To Be Assigned |
| | Attorney Docket No. | 12279-187-999 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|----------|--|-----------------------------|--|---|---|
| *Examiner Initials | Cite No. | Foreign Patent Document Country Code, Number, Kind Code (if known) | Publication Date mm/dd/yyyy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
| | B05 | WO 00/36103 | 6/22/2000 | Genetics Institute, Inc. and John Hopkins University | | |
| | B06 | WO 02/055100 | 7/18/2002 | Genetics Institute, LLC and the Government of the United States as Represented by the Secretary of the Department of Health and Human Services | | |
| | B07 | WO 03/018635 A1 | 3/06/2003 | Kyowa Hakko Kogyo Co., Ltd | | |
| | B08 | WO 2005/062967 A2 | 7/14/2005 | Tanox, Inc. | | |
| | B09 | WO 2005/062972 A2 | 7/14/2005 | Tanox, Inc. | | |
| | B10 | WO 2008/140455 A1 | 11/20/2008 | Tanox, Inc. | | |
| | B11 | WO 89/04838 | 6/01/1989 | Immunex Corporation | | |
| | B12 | WO 91/09059 | 6/27/1991 | Schering Corporation | | |
| | B13 | WO 93/15766 | 8/19/1993 | Seragen, Inc. | | |
| | B14 | WO 94/04680 | 3/03/1994 | Schering Corporation | | |
| | B15 | WO 94/14975 | 7/07/1994 | Schering Corporation | | |
| | B16 | WO 95/14780 | 6/01/1995 | Schering Corporation | | |
| | B17 | WO 97/15663 | 5/01/1997 | Amrad Operations Pty. Ltd. | | |
| | B18 | WO 97/29131 | 8/14/1997 | Basf Ak-Tiengesellschaft | | |
| | B19 | WO 97/31946 | 9/04/1997 | Genetics Institute, Inc. | | |
| | B20 | WO 97/47742 | 12/18/1997 | Smithkline Beecham Corporation and Human Genome Sciences, Inc. | | |
| | B21 | WO 98/10638 | 3/19/1998 | Amrad Operations Pty. Ltd. | | |
| | B22 | WO 98/30240 | 7/16/1998 | Biogen, Inc. | | |
| | B23 | WO 2005/007699 A2 | 01/27/2005 | Cambridge Antibody Technology Limited | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|--|---|
| *Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
| | C01 | ANDREWS et al., 2002, "Kinetic analysis of the interleukin-13 receptor complex," J. Biol. Chem., Vol. 277(48):46073-46078 | |
| | C02 | BELLANTI, 1998, "Cytokines and allergic diseases: Clinical aspects," Allergy and Asthma, Proc., Vol. 19(6):337-340 | |

NYI-4201601v2

| | |
|---|------------------------|
| EXAMINER SIGNATURE | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | |
|---|-----------------------------|-------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | Application Number | 10/583,927 |
| | Filing Date | December 23, 2004 |
| | First Named Inventor | Sek Chung Fung |
| | Art Unit | 1643 |
| | Examiner Name | To Be Assigned |
| | Attorney Docket No. | 12279-187-999 |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|----------|---|---|
| | C03 | BLANCHARD et al., 2005, "Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354)," Clin. Exp. Allergy, Vol. 35:1096-1103 | |
| | C04 | BOST et al., 1996, "In vivo treatment with anti-interleukin-13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice," Immunology, Vol. 87(4):633-641 | |
| | C05 | BREE et al., 2007, "IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys," J. Allergy Clin. Immunol., Vol. 119(5):1251-1257 | |
| | C06 | BRINKMANN et al., 1995, "TCR-stimulated naive human CD4 ⁺ 45R0 ⁺ T cells develop into effector cells that secrete IL-13, IL-5, and IFN- γ , but no IL-4, and help efficient IgE production by B cells," J. Immunol., Vol. 154(7):3078-3087 | |
| | C07 | CAMPBELL et al., 2003, "Allergic humans are hypo-responsive to CXCR3 chemokines in a Th1 immunity-promoting loop," FASEB J., Vol. 18(2):329-331 | |
| | C08 | CAPUT et al., 1996, "Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor α chain," J. Biol. Chem., Vol. 271(28):16921-16926 | |
| | C09 | CARBALLIDO et al., 1995, "IL-4 induces human B cell maturation and IgE synthesis in SCID-hu mice," J. Immunol., Vol. 155(9):4162-4170 | |
| | C10 | CASOLARO et al., 1996, "Biology and genetics of atopic disease," Curr. Opin. Immunol., Vol. 8:796-803 | |
| | C11 | De VRIES et al., 1996, "Modulation of the human IgE response," Eur. Respir. J., Suppl. 22:58s-62s | |
| | C12 | DE VRIES, 1994, "Novel fundamental approaches to intervening in IgE-mediated allergic diseases," J. Invest. Dermatol., Vol. 102:141-144 | |
| | C13 | DEBINSKI et al., 1995, "A novel chimeric protein composed on interleukin 13 and pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4," J. of Biological Chemistry, Vol. 270(28):16775-16780 | |
| | C14 | DEBINSKI et al., 1995, "Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitivity to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin," Clinical Cancer Research, Vol. 1:1253-258 | |
| | C15 | DONALDSON et al., 1998, "The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1," J. Immunol., Vol. 161:2317-2324 | |
| | C16 | DOUCET et al., 1998, "Interleukin (IL) 4 and IL-13 act on human lung fibroblasts," J. Clin. Invest., Vol. 101:2129-2139 | |
| | C17 | ECONOMIDES, et al., 1995, "Designer cytokines: Targeting actions to cells of choice," Science, Vol. 270:1351-1353 | |
| | C18 | ENOMOTO et al., 2002, "High-throughput miniaturized immunoassay for human interleukin-13 secreted from NK3.3 cells using homogenous time-resolved fluorescence," J of Pharm and Biomedical Analysis, Vol. 28:73-79 | |
| | C19 | FAUCI et al., 1998, "Harrison's Principles Of Internal Medicine," 14 th Edition, Mc Graw-Hill Companies, Inc., New York, NY, pp. 1419-1420, 1760-1761 | |
| | C20 | FICHTNER-FEIGL et al., 2005, "IL-13 signaling through the IL-13 α_2 receptor is involved in induction of TGF- β_1 production and fibrosis," Nature Medicine, Vol. 12: 99-106 | |
| | C21 | GABRIELSSON et al., 1998, "Increased frequencies of allergen-induced interleukin-13 producing cells in atopic individuals during the pollen season," Scand. J. Immunol., Vol. 48:429-435 | |
| | C22 | GHAFFAR et al., 1997, "IL-13 mRNA and immunoreactivity in allergen-induced rhinitis: Comparison with IL-4 expression and modulation by topical glucocorticoid therapy," Am. J. Respir. Cell Mol. Biol., Vol. 17:17-24 | |
| | C23 | GHAMDI et al., 1997, "IL-4 and IL-3 expression in chronic sinusitis: Relationship with cellular infiltrate and effect of topical corticosteroid treatment," J. of Otolaryngology, Vol. 26(3):160-166 | |
| | C24 | GRÜNIG et al., 1998, "Requirement for IL-13 independently of IL-4 in experimental asthma," Science, Vol. 282:2261-2263 | |

NY1-4201601v2

| | |
|---|------------------------|
| EXAMINER SIGNATURE | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | |
|---|-----------------------------|-------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | Application Number | 10/583,927 |
| | Filing Date | December 23, 2004 |
| | First Named Inventor | Sek Chung Fung |
| | Art Unit | 1643 |
| | Examiner Name | To Be Assigned |
| | Attorney Docket No. | 12279-187-999 |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|----------|--|---|
| | C25 | HAMID et al., 1996, "In vivo expression of IL-12 and IL-13 in atopic dermatitis," J. Allergy Clin. Immunol., Vol. 98:225-231 | |
| | C26 | HUANG et al., 1995, "IL-13 expression at the sites of allergen challenge in patients with asthma," J. Immunol., Vol. 155:2688-2694 | |
| | C27 | HUMBERT et al., 1997, "Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma," J. Allergy Clin. Immunol., Vol. 99:657-665 | |
| | C28 | JANEWAY and TRAVERS, 1997, "Immunobiology: The Immune System In Health And Disease," 3 rd Edition, Current Biology Ltd. and Garland Publishing Inc., pp. 12:8-12:11 | |
| | C29 | KAPP et al., 1999, "Interleukin 13 is secreted by and stimulated the growth of Hodgkin and Reed-Sternberg Cells," J. Exp. Med., Vol. 189(12):1939-1945 | |
| | C30 | KASAIAN et al., 2007, "Efficacy of IL-13 neutralization in a sheep model of experimental asthma," Am. J. Respir. Cell Mol. Biol., Vol. 36:368-376 | |
| | C31 | KAWAKAMI et al., 2001, "Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer," Cancer Research, Vol. 61:6194-6200 | |
| | C32 | KIMATA et al., 1995, "Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephritic syndrome," Eur. J. Immunol., Vol. 25:1497-1501 | |
| | C33 | KOTSIMBOS et al., 1996, "Interleukin-13 and interleukin-4 are coexpressed in atopic asthma," Proceedings of the Assoc. of American Physicians, Vol. 108(5):368-373 | |
| | C34 | KROEGEL et al., 1996, "Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts," Eur. Respir. J., Vol. 9:899-904 | |
| | C35 | LEVY et al., 1997, "Role of IL-13 in CD4 T cell-dependent IgE production in atopy," Int. Arch. Allergy Immunol., Vol. 112:49-58 | |
| | C36 | MAINI et al., 1997, "Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of pseudomonas exotoxin," J. Urology, Vol. 158:948-953 | |
| | C37 | MARSH et al., 1994, "Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations," Science, Vol. 264:1152-1156 | |
| | C38 | McKENZIE et al., 1993, "Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function," Proc. Natl. Acad. Sci. U.S.A., Vol. 90(8):3735-3739 | |
| | C39 | McKENZIE et al., 1994, "Measurement of interleukin-13," Current Protocols in Immunology, Unit 6.18, Suppl. 10:6.18.1-6.18.5, Coligan et al. eds., John Wiley & Sons, New York | |
| | C40 | McKENZIE et al., 1998, "Impaired development of Th2 cells in IL-13 deficient mice," Immunity, Vol. 9:423-432 | |
| | C41 | MENTINK-KANE et al., 2004, "Opposing roles for IL-13 and IL-13 receptor $\alpha 2$ in health and disease," Immunological Reviews, Vol. 202:191-202 | |
| | C42 | NASEER et al., 1997, "Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy," Am. J. Respir. Crit. Care Med., Vol. 155:845-851 | |
| | C43 | OHNO et al., 1985, "Antigen-binding specificities of antibodies are primarily determined by seven residues of VH," Proc. Natl. Acad. Sci. U S A., Vol. 82(9):2945-2949 | |
| | C44 | OSHIMA et al., 2001, "Characterization of a powerful high affinity antagonist that inhibits biological activities of human interleukin-13," J. Biol. Chem., Vol. 276(18):15185-15191 | |
| | C45 | PAWANKAR et al., 1997, "Nasal mast cells in perennial allergic rhinitis exhibit increased expression of the Fc ϵ RI, CDR40L, IL-4, and IL-13, and can induce IgE synthesis in B cells," J. Clin. Invest., Vol. 99(7):1492-1499 | |
| | C46 | POSTMA et al., 1995, "Genetic susceptibility to asthma - Bronchial hyperresponsiveness coinherited with a major gene for atopy," N. Engl. J. Med., Vol. 333(14):894-900 | |
| | C47 | PUNNONEN et al., "Cytokines and IgE regulation," Allergy and Allergic Diseases: The New Mechanisms and | |

NY1-4201601v2

| | |
|---|------------------------|
| EXAMINER SIGNATURE | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

| | |
|-----------------------------|-------------------|
| Application Number | 10/583,927 |
| Filing Date | December 23, 2004 |
| First Named Inventor | Sek Chung Fung |
| Art Unit | 1643 |
| Examiner Name | To Be Assigned |
| Attorney Docket No. | 12279-187-999 |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|----------|---|---|
| | | Therapeutics, pp. 13-40, Edited by J.A. Denburg, Human Press Inc., Totowa, NJ 1998 | |
| | C48 | ROITT et al., 1996, Immunology, Fourth Edition, Published by Mosby, London, pp. 22-1-22.5 and glossary | |
| | C49 | ROITT et al., Immunology, 2000, Publisher "Mir", Moscow, pages 110-111. | |
| | C50 | ROITT, I.M., 1988, Essential Immunology, Sixth Edition, Blackwell Scientific Publications, Oxford, pp. 195-196 | |
| | C51 | SCHILDBACH et al., 1993, "Modulation of antibody affinity by a non-contact residue," Protein Sci. Vol. 2(2):206-14 | |
| | C52 | SKINNIDER et al., 2002, "Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma," Blood, Vol. 99(2):618-626 | |
| | C53 | SKINNIDER et al., 2002, "The role of interleukin 13 in classical Hodgkin lymphoma," Leuk. Lymphoma, Vol. 43(6):1203-1210 | |
| | C54 | TEKKANAT et al., 2001, "IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent," J. Immunol., Vol. 166:3542-3548 | |
| | C55 | TERABE et al., 2000, "NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway," Nat. Immunol., Vol. 1(6):515-520 | |
| | C56 | TERABE et al., 2004, "Role of IL-13 in regulation of anti-tumor immunity and tumor growth," Cancer Immunol. Immunother., Vol. 53:79-85 | |
| | C57 | TRIEU et al., "Inhibition of Hodgkin lymphoma cell line growth using an adenovirus expressing the soluble IL-13 decoy receptor (sIL-13Ralpha2)," Blood vol. 100(11):Abstract no. 2272 & 44 Annual meeting of the American Society of Hematology; Philadelphia, PA, USA, December 6-10, 2002 | |
| | C58 | TRIEU et al., 2004, "Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo," Cancer Research, Vol. 64:3271-3275 | |
| | C59 | VAN DER POUW KRAAN et al., 1996, "Human IL-13 production is negatively influenced by CD3 engagement - enhancement of IL-13 production by cyclosporine A," J. Immunol., Vol. 156(5):1818-1823 | |
| | C60 | VAN DER POUW KRAAN et al., 1998, "The role of IL-13 in IgE synthesis by allergic asthma patients," Clin. Exp. Immunol., Vol. 111:129-135 | |
| | C61 | VUGMEYSTER et al., 2008, "Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms," Intl. Immunopharmacol., Vol. 8:477-483 | |
| | C62 | WARNER, 1998, "Bronchial hyperresponsiveness, atopy, airway inflammation, and asthma," Pediatr. Allergy Immunol., Vol. 9:56-60 | |
| | C63 | WILLS-KARP et al., 1998, "Interleukin-13: central mediator of allergic asthma," Science, Vol. 282:2258-2261 | |
| | C64 | WOOD et al., 2003, "Enhanced interleukin (IL) -13 responses in mice lacking IL-13 receptor alpha 2," J. Exp. Med., Vol. 197(6):703-709 | |
| | C65 | WORLD HEALTH ORGANIZATION, 1992, "International statistical classification of diseases and related health problems," 10 TH Revision, Vol. 1, pp. 536-537 | |
| | C66 | WYNN, T. A., 2003, "IL-13 effector functions," Annual Review of Immunol., Vol. 21:425-456 | |
| | C67 | YANG et al., 2004, "Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling," Cytokine, Vol. 28:224-232 | |
| | C68 | YANG et al., 2005, "Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice," J. Pharmacol. Exp. Ther., Vol. 312:8-15 | |
| | C69 | YSSEL et al., 1998, "The role of IgE in asthma," Clin. Exp. Allergy, Vol. 28, Supp. 5:104-109 | |

NY1-4201601v2

**EXAMINER
SIGNATURE**

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|---|-----------------------------|-------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | Application Number | 10/583,927 |
| | Filing Date | December 23, 2004 |
| | First Named Inventor | Sek Chung Fung |
| | Art Unit | 1643 |
| | Examiner Name | To Be Assigned |
| | Attorney Docket No. | 12279-187-999 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|----------|--|---|
| *Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
| | C70 | ZHANG et al. 1997, "Identification, purification, and characterization of a soluble interleukin (IL)—13-binding protein," J. of Biol. Chem., Vol. 272(14):9474-9480 | |
| | C71 | ZHANG et al., 2003, "Identification and application of monoclonal antibodies against IL-6," Molecular Cardiology of China, Vol. 3(3):152-156 | |

NYI-4201601v2

| | |
|---|------------------------|
| EXAMINER SIGNATURE | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |